Public Meeting on Patient Focused Drug Development for Alpha 1 Antitrypsin Part 2

On September 29, 2015, FDA hosted a public meeting on Patient-Focused Drug Development for Alpha-1 Antitrypsin. FDA was interested in obtaining patient perspectives on the impact of Alpha-1 Antitrypsin on daily life and patient views on treatment approaches. For more information, visit go.usa.gov/xHpRE.